OncoMatch/Clinical Trials/NCT06451211
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
Is NCT06451211 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tislelizumab and Oxaliplatin for stomach neoplasms.
Treatment: Tislelizumab · Oxaliplatin · S-1 · Capecitabine — The aim of this study is to test the efficacy and safety of immunotherapy plus chemotherapy on people with a relatively rare type of gastric cancer. Participants will take the anti-PD-1 inhibitor (Tislelizumab) and platinum-based chemotherapy (oxaliplatin + capecitabine or oxaliplatin + S-1) in a 3-week cycle, followed by a radical operation after 6 cycles.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Disease stage
Required: Stage CT1-2N+M0, CT3-4NANYM0
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: cytotoxic chemotherapy
Previous cytotoxic chemotherapy
Cannot have received: radiation therapy
Previous...radiotherapy
Cannot have received: immunotherapy
Previous...immunotherapy
Lab requirements
Blood counts
white blood cell count > 4*10^9/l, neutrophil cell count > 1.5*10^9/l, hemoglobin > 90 g/l, platelet count > 100*10^9 /l
Kidney function
creatinine ≤ 1.5 ×uln or serum clearance > 60 ml/min
Liver function
serum bilirubin ≤ 1.5×uln, ast, alt ≤ 2.5×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify